Vimian Group stock
VIMIAN.STSTOVimian Group AB (publ), HealthcareISIN SE0015961982
58Score 58 out of 100, Neutral
Price and trend
86 / 100
Price history
+37% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 33% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is at its 52-week high. Largest decline in 5 years: 83% (July 2021 to October 2023).
Chart figures for advanced users
- SMA 50$3.77
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.20
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.51
- The lowest closing price of the last twelve months.
- Resistance$4.26
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Vimian Group AB (publ) belongs to the Medical (Diagnostics & Research) industry (Sweden) and, with a market value of $2.24B, is number 28 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $472.9M (up 13.4% year on year) and earnings of $34.83M (up 69.2%).
- MEQIRI Score 58 out of 100 (Neutral): rank 311 of 714 in Healthcare, median 53.
Show more
- The P/E is 52.1 (Medical (Diagnostics & Research) median 33.7, own median of recent years 94.2).
- Our model puts fair value at $3.04, with the price 39% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 25.3% a year since 2020, Medical (Diagnostics & Research) median 6.6%.Growth 54
- Earnings turn into cashFree cash flow 232% of earnings over the last 12 months.Fundamentals 59
- Analysts expect strong earnings growthUp 23.5% a year through 2028 (estimates from 6 analysts).Growth 54
Weaknesses
- DilutionShare count up 40% since 2020.Capital allocation 31
- Earnings per share fallingDown 15.6% a year since 2020.Growth 54
Its standout strengths are momentum and technical analysis, while capital allocation and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $2.34 and expensive above $4.34 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $3.32 (cash-flow model) and $2.75 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.6%. At 8.6% the fair value would be $2.79, at 6.6% it would be $3.41.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10.8% on the twelve months before. Revenue has grown strongly since 2018, at around 76% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 69%, operating 17%, net 7%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 22 Oct 2026EPS reported 0.22 (expected 0.26)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 4.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- 0.1−4.6%
- Revenue
- $528.05M+0.2%
- Earnings per share
- 0.13−1.6%
- Revenue
- $588.67M+1.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +5.4%No specific guidance; continued slow single-digit growth is expected in the US orthopedic business in the second half.
“Orthopedic business will continue, and we expect a continued slow single digit growth in the second half of the year as well.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 17 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Vimian Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- BillionToOneBLLN $5.27B64
- DiaSorinDIA.MI $5.14B67
- Sotera HealthSHC $4.69B55
- CareDxCDNA $4.26B59
- NeoGenomicsNEO $2.19B40
- VeracyteVCYT $2.03B53
- PersonalisPSNL $1.73B41
- GeneDx HoldingsWGS $1.64B37
ETFs that hold Vimian Group
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.10% | 0.23% | €319.31M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.04% | 0.30% | €3.43B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.35% | €434.1M |
Show 4 more
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.02% | 0.30% | €810.11M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = SEK 9.9317, $1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 12 Jun 2026)
- Valuation signal Fairly valued since 8 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.